{"url_path":"/sec/stro/8-k/2026-06-08/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-08","source_url":"https://www.sec.gov/Archives/edgar/data/1382101/0001193125-26-261658-index.html","accession_number":"0001193125-26-261658","cik":"0001382101","ticker":"STRO","issuer_name":"SUTRO BIOPHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1382101/0001193125-26-261658-index.html","primary_entity_key":"0001382101","primary_entity_name":"SUTRO BIOPHARMA, INC."},"word_count":226,"has_tables":true,"body_markdown":"Item 5.07. Submission of Matters to a Vote of Security Holders.\n\nOn June 5, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), and the following proposals were adopted:\n\n \n\n \n1.\n\nElection of three Class II directors, identified in the table below, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until their earlier resignation or removal:\n\n \n\nNominees\n\n  \nShares\nFor\n \n  \nShares\nWithheld\n \n  \nBroker\nNon-Votes\n \n\nJane Chung\n\n  \n \n11,355,214\n \n  \n \n3,596\n \n  \n \n2,540,863\n \n\nConnie Matsui\n\n  \n \n9,734,802\n \n  \n \n1,624,008\n \n  \n \n2,540,863\n \n\nJames Panek\n\n  \n \n9,706,422\n \n  \n \n1,652,388\n \n  \n \n2,540,863\n \n\n \n\n \n2.\n\nRatification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:\n\n \n\nShares\n\nFor\n\n \n\nShares\n\nAgainst\n\n \n\nShares\n\nAbstaining\n\n13,893,289\n\n \n\n501\n\n \n\n5,883\n\n \n\n \n3.\n\nApproval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting:\n\n \n\nShares\n\nFor\n\n \n\nShares\n\nAgainst\n\n \n\nShares\n\nAbstaining\n\n \n\nBroker\n\nNon-Votes\n\n11,329,946\n\n \n\n22,412\n\n \n\n6,452\n\n \n\n2,540,863\n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nSutro Biopharma, Inc.\n\nDate: June 8, 2026\n \n\n \nBy:\n \n\n/s/ Greg Chow\n\n \n\n \n\n \nGreg Chow\n\n \n\n \n\n \nChief Financial Officer"}